Incidence and time trends of soft tissue sarcomas in German children 1985–2004 – A report from the population-based German Childhood Cancer Registry

2008 ◽  
Vol 44 (3) ◽  
pp. 432-440 ◽  
Author(s):  
Thomas Weihkopf ◽  
Maria Blettner ◽  
Tobias Dantonello ◽  
Irene Jung ◽  
Thomas Klingebiel ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Childhood Cancer ◽  
Cancer Registry ◽  
Time Trends ◽  
Soft Tissue Sarcomas ◽  
Population Based ◽  
German Children ◽  
German Childhood Cancer Registry

scholarly journals Risk of late health effects after soft-tissue sarcomas in childhood – a population-based cohort study within the Adult Life after Childhood Cancer in Scandinavia research programme

2020 ◽  
Vol 59 (10) ◽  
pp. 1246-1256
Author(s):  
Filippa Nyboe Norsker ◽  
Cristina Boschini ◽  
Catherine Rechnitzer ◽  
Anna Sällfors Holmqvist ◽  
Laufey Tryggvadottir ◽  
...  
Keyword(s):  
Cohort Study ◽  
Soft Tissue ◽  
Childhood Cancer ◽  
Health Effects ◽  
Adult Life ◽  
Soft Tissue Sarcomas ◽  
Research Programme ◽  
Population Based

scholarly journals Population-based Aarhus Sarcoma Registry: validity, completeness of registration, and incidence of bone and soft tissue sarcomas in western Denmark

2013 ◽  
pp. 45 ◽  
Author(s):  
Katja Maretty-Nielsen ◽  
Aggerholm-Pedersen ◽  
Keller ◽  
Safwat ◽  
Baerentzen ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcomas ◽  
Population Based

Incidence of unplanned excisions of soft tissue sarcomas in the Netherlands: A population-based study

2021 ◽  
Author(s):  
Annemarie S. Melis ◽  
Melissa Vos ◽  
Melinda S. Schuurman ◽  
Thijs van Dalen ◽  
Winan J. van Houdt ◽  
...  
Keyword(s):  
Soft Tissue ◽  
The Netherlands ◽  
Soft Tissue Sarcomas ◽  
Population Based ◽  
Population Based Study

scholarly journals A study of soft tissue sarcomas after childhood cancer in Britain

2007 ◽  
Vol 97 (5) ◽  
pp. 695-699 ◽  
Author(s):  
H C Jenkinson ◽  
D L Winter ◽  
H B Marsden ◽  
M A Stovall ◽  
M C G Stevens ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Childhood Cancer ◽  
Soft Tissue Sarcomas

The aetiology of second soft tissue sarcomas occurring after childhood cancer in Britain

2001 ◽  
Vol 37 ◽  
pp. S333
Author(s):  
H.C. Jenkinson ◽  
M.M. Hawkins ◽  
D.L. Winter ◽  
M.C.G. Stevens ◽  
C.A. Stiller ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Childhood Cancer ◽  
Soft Tissue Sarcomas

Neuroblastoma metastatic to the central nervous system: Survival analyses from the German Childhood Cancer Registry and the literature.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 10555-10555
Author(s):  
Frank Berthold ◽  
Marc Hömberg ◽  
Ole Baadsgaard
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Childhood Cancer ◽  
Cancer Registry ◽  
Natural Course ◽  
Curative Intent ◽  
Term Survival ◽  
The Central Nervous System ◽  
Inclusive Analysis ◽  
German Childhood Cancer Registry

10555 Background: Therapeutic innovation has resulted in an overall decline in childhood neuroblastoma (NB) mortality; however, metastatic NB to the central nervous system (CNS NB), which has emerged as a sanctuary site for NB metastases, remains difficult to treat and is typically fatal. The objective of this study was to describe the natural course of CNS NB. Methods: Data were sourced from a custom query of the German Childhood Cancer Registry (GCCR) and from the literature. Survival statistics were prepared from a diverse, thus generalizable, pool of CNS NB patients. Data are presented as secondary event-free and overall survival (EFS and OS) after diagnosis of first CNS recurrence from initial high-risk NB. Results: The GCCR query identified 85 patients with CNS NB diagnosed from 1990–2010, including 57 with isolated CNS disease. The median (95% confidence) EFS and OS times were 2.6 (1.5–3.8) and 4.7 (2.1–7.2) months, respectively, for all CNS NB patients, and 2.8 (1.4–4.1) and 6.8 (2.1–11.5) months, respectively, for isolated CNS NB patients. Secondary OS at 12, 18, and 36 months was 29.4%, 18.8%, and 8.2%, respectively, for all CNS NB patients, and 35.1%, 22.8%, and 12.3%, respectively, for isolated CNS NB patients. Thirteen publications were selected with 83 patients treated from 1979–2013. In addition to an inclusive analysis, a restricted analysis was performed, excluding patients who did not receive therapy with curative intent, to assess survival after therapeutic intervention. Median OS (95% confidence) was 5.6 (3.0–8.0) and 8.7 (5.8–11.0) months in the inclusive and restricted analyses, respectively. The proportion of patients surviving 12, 18, and 36 months at reporting were 24%, 12%, and 3.6%, respectively, for the inclusive population, and 33%, 17%, and 5%, respectively, for the restricted population. Conclusions: An assessment of the natural course of CNS NB from two sources arrived at similar conclusions with respect to overall and long-term survival. In general, median secondary OS is < 6 months and < 10% of patients survive 36 months. The findings were consistent across geographic regions and have not changed appreciably in 4 decades.

Sign in / Sign up

Export Citation Format

Share Document